30 May 2022

Covalab invests more than €1 million in bioproduction operations for antibodies for Covid-19 diagnostics

Bron, France, May 23, 2022 – Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and antibodies for diagnostics and therapeutics, today announces that its BioDiaThera project has been awarded €491,152 ($520k) in funding as part of the French ‘Capacity Building’ scheme; part of the ‘France 2030’ investment roadmap. Launched by the French government, this scheme is intended to strengthen national production capability in response to the Covid-19 pandemic. Covalab also plans to invest €566k ($600k) of its own funds into the project, taking the total investment to over €1 million ($1.06M). To know more